Alx oncology announces two evorpacept abstracts accepted for poster presentation at 2024 asco annual meeting

South san francisco, calif., april 24, 2024 (globe newswire) -- alx oncology holdings inc., (“alx oncology” or “the company”) (nasdaq: alxo), an immuno-oncology company developing therapies that block the cd47 immune checkpoint pathway, today announced the acceptance of two abstracts for poster presentation at the american society of cancer oncology (“asco”), which will be held in chicago from may 31-june 4, 2024.
ALXO Ratings Summary
ALXO Quant Ranking